Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 27;61(7):e00464-17.
doi: 10.1128/AAC.00464-17. Print 2017 Jul.

Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration

Affiliations

Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration

Eric Wenzler et al. Antimicrob Agents Chemother. .

Abstract

Ceftazidime-avibactam administered at 1.25 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa bacteremia in a critically ill patient on continuous venovenous hemofiltration (CVVH). Prefiltration plasma drug concentrations of ceftazidime and avibactam were measured at 0, 1, 2, 4, 6, and 8 h along with postfiltration and ultrafiltrate concentrations at h 2 and h 6. Plasma pharmacokinetic parameters of ceftazidime and avibactam, respectively, were as follows: maximum plasma concentration (Cmax), 61.10 and 14.54 mg/liter; minimum plasma concentration (Cmin), 31.96 and 8.45 mg/liter; half-life (t1/2), 6.07 and 6.78 h; apparent volume of distribution at the steady state (Vss), 27.23 and 30.81 liters; total clearance at the steady state (CLss), 2.87 and 2.95 liters/h; area under the concentration-time curve from 0 to 8 h (AUC0-8), 347.87 and 85.69 mg · h/liter. Concentrations of ceftazidime in plasma exceeded the ceftazidime-avibactam MIC (6 mg/liter) throughout the 8-h dosing interval. Mean CVVH extraction ratios for ceftazidime and avibactam were 14.44% and 11.53%, respectively, and mean sieving coefficients were 0.96 and 0.93, respectively. The calculated mean clearance of ceftazidime by CVVH was 1.64 liters/h and for avibactam was 1.59 liters/h, representing 57.1% of the total clearance of ceftazidime and 54.3% of the total clearance of avibactam. Further data that include multiple patients and dialysis modes are needed to verify the optimal ceftazidime-avibactam dosing strategy during critical illness and CVVH.

Keywords: avibactam; ceftazidime; dialysis; hemofiltration; pharmacokinetics; renal replacement.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Prefiltration concentration-time profiles of ceftazidime (solid line, filled circles) and avibactam (dotted line, open circles) in plasma before and after the fourth dose of ceftazidime-avibactam (1.25 g) in relation to the MIC of the infecting P. aeruginosa pathogen (dashed horizontal line). The shaded region represents the infusion period, accounting for overfill volume and residual fluid volume in the tubing. Data in the y axis are in the log scale.

References

    1. Zasowski EJ, Rybak JM, Rybak MJ. 2015. The beta-lactams strike back: ceftazidime-avibactam. Pharmacotherapy 2015:755–770. doi:10.1002/phar.1622. - DOI - PMC - PubMed
    1. . September 2015. Avycaz (ceftazidime/avibactam) prescribing information. Actavis, Inc; http://pi.actavis.com/data_stream.asp?product_group=1957&p=pi&language=E Accessed 14 September 2015.
    1. . 5 December 2014. Food and Drug Administration Anti-Infective Drugs Advisory Committee Meeting. Ceftazidime-avibactam for injection for treatment of complicated intra-abdominal infection (used in combination with metronidazole), complicated urinary tract infection including acute pyelonephritis, and limited use indication: aerobic Gram-negative infections with limited treatment options. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria... Accessed 25 August 2016.
    1. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 28 December 2016. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother doi:10.1128/aac.02097-16. - DOI - PMC - PubMed
    1. Xipell M, Bodro M, Marco F, Losno RA, Cardozo C, Soriano A. 2017. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 49:266–268. doi:10.1016/j.ijantimicag.2016.11.005. - DOI - PubMed

MeSH terms

LinkOut - more resources